JPM 2024 Day 3: Biotech Updates from Verve, Roivant, etc

InhonorofJPMWeek,you’rereadingaspecialeditionofourbiotechnewsletter,TheReadout.Tostayontopofthelates 1:29AlanArkinattendsthe26thAnnualScreenActorsGuildAwardsatTheShrineAuditoriumonJan.19,2020inLosAngel




leisure time

author：Wikipedia    Page View：3
Franklin faces
Adobe

ARCH Venture Partners, one of the top investors in the biotech ecosystem, is raising $3 billion for a new fund.

The Chicago-based firm filed paperwork with the Securities and Exchange Commission this week for what would be its 13th namesake fund. Arch estimated it would raise around $3 billion — roughly the same amount it raised during its more recent fundraising in 2022.

advertisement

Arch declined to comment on the new fundraising.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In
Previous article： Ahead of JPM, here's who's profiting most in health care
Next article： Medical records are filled with copy